XML 48 R38.htm IDEA: XBRL DOCUMENT v3.25.1
MAJOR CUSTOMERS, PARTNERSHIPS AND STRATEGIC ALLIANCES - Pfizer Inc. (Details)
$ in Thousands
1 Months Ended 3 Months Ended 12 Months Ended 44 Months Ended 95 Months Ended
Dec. 31, 2024
May 31, 2017
USD ($)
Mar. 31, 2025
USD ($)
Mar. 31, 2024
USD ($)
Dec. 31, 2025
USD ($)
Dec. 31, 2020
USD ($)
Mar. 31, 2025
USD ($)
milestone
Research and Development Arrangement, Contract to Perform for Others [Line Items]              
Revenues     $ 6,437 $ 481      
Forecast | Subsequent Event              
Research and Development Arrangement, Contract to Perform for Others [Line Items]              
Agreement termination, consideration         $ 5,000    
Pfizer Inc.              
Research and Development Arrangement, Contract to Perform for Others [Line Items]              
Agreement termination, term   15 years          
Pfizer Inc. | License              
Research and Development Arrangement, Contract to Perform for Others [Line Items]              
Revenues under agreement   $ 70,000          
Potential amount to be funded for achievement of specified commercialized and sales milestones   $ 266,500          
Collaborative arrangement, number of milestones achieved | milestone             2
Milestone payments received             $ 55,000
Revenue, performance obligation, termination fee, payable term     60 days        
Revenue, performance obligation, termination fee, payable term if sublicense transfers 30 days            
Revenues     $ 5,000 $ 0   $ 134,000  
Pfizer Inc. | License | Minimum              
Research and Development Arrangement, Contract to Perform for Others [Line Items]              
Percentage of net sales per developed licensed product which will trigger royalties by counterparty   14.00%          
Pfizer Inc. | License | Maximum              
Research and Development Arrangement, Contract to Perform for Others [Line Items]              
Percentage of net sales per developed licensed product which will trigger royalties by counterparty   20.00%          
Pfizer Inc. | License | Achievement of specified clinical development intellectual property and regulatory milestones              
Research and Development Arrangement, Contract to Perform for Others [Line Items]              
Development and sales-based milestone payments to be received   $ 208,500